Breast Cancer Core Needle Biopsy Market

Breast Cancer Core Needle Biopsy Market Analysis and Forecast by Fact.MR

• The global breast cancer core needle biopsy market is estimated at US$ 0.9 billion in 2025, forecast to expand at a CAGR of 4.7% to reach US$ 1.5 billion by 2036.
• Core needle biopsy devices include spring loaded automated biopsy needles, vacuum assisted biopsy systems, manual biopsy needles, and associated accessories used for tissue sampling of breast lesions detected through mammography, ultrasound, or MRI guided imaging.
• Demand is shaped by rising breast cancer screening rates, growing preference for minimally invasive tissue sampling over surgical biopsy, and expanding diagnostic imaging center capacity across developed and developing markets.

Summary of Breast Cancer Core Needle Biopsy Market

• Market Snapshot
  • In 2025, the global Breast Cancer Core Needle Biopsy Market was valued at approximately USD 0.9 billion.
  • The market is estimated to reach USD 1 billion in 2026 and is projected to attain USD 1.5 billion by 2036.
  • The breast cancer core needle biopsy market is likely to expand at a CAGR of 4.7% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 0.6 billion between 2026 and 2036.
  • Core Needle Biopsy Devices account for 46% of product type share in 2026.
  • China (5%) and India (4.7%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Rising breast cancer screening rates across developed and developing markets are increasing the volume of suspicious lesions requiring tissue biopsy for diagnosis.
  • Growing preference for minimally invasive core needle biopsy over open surgical biopsy is increasing device utilization and reducing patient procedure burden.
  • Expanding diagnostic imaging center infrastructure with integrated biopsy capability is creating new procedure capacity in ambulatory and community settings.
  • Expanding institutional procurement and infrastructure development across emerging economies is increasing demand.
  • Product innovation and technology advancement are broadening market access and application scope.
• Product and Segment View
  • Core Needle Biopsy Devices account for 46% of the product type segment in 2026, supported by established use and procurement patterns.
  • Breast Cancer Diagnosis accounts for 54% of the application segment in 2026.
  • Key segmentation includes:
    • Product Type: Core Needle Biopsy Devices, Manual Biopsy Needles, Vacuum Assisted Biopsy Systems, Biopsy Accessories
    • Application: Breast Cancer Diagnosis, Lesion Characterization, Follow Up Diagnostics, Screening Programs
    • End Use: Hospitals, Diagnostic Imaging Centers, Specialty Clinics
    • Technology: Image Guided Biopsy Technology, Stereotactic Biopsy Technology, Vacuum Assisted Technology, Automation Technology
    • Formulation: Sterile Disposable Devices, Tissue Preservation Solutions, Biopsy Kits, Marking and Tracking Devices
    • Distribution Channel: Hospital Procurement, Medical Device Distributors, Online Sales
  • These systems enable:
    • Minimally invasive tissue sampling of breast lesions for histological diagnosis without surgical excision
    • Image guided precision targeting of suspicious lesions detected through mammography, ultrasound, or MRI screening
    • Vacuum assisted tissue acquisition providing larger tissue specimens for improved diagnostic accuracy and lesion characterization
• Geography and Competitive Outlook
  • China leads growth at 5.0%, supported by expanding breast cancer screening programs, growing diagnostic imaging capacity, and rising breast cancer detection rates.
  • India at 4.7% reflects increasing breast cancer awareness, expanding hospital biopsy capability, and growing adoption of image guided tissue sampling techniques.
  • North America remains the largest market with the USA at 4.5%, driven by established screening programs, high diagnostic imaging utilization, and premium device preference.
  • Key companies include Hologic Inc., Intact Medical Corporation, Ethicon Surgical Technologies, Gallini SRL, Leica Biosystems Nussloch GmbH, and Argon Medical Devices, Encapsule Medical Devices LLC, Cook Medical Incorporated, Becton, Dickinson and Company, C.R. Bard Inc..
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The breast cancer core needle biopsy market is a mature diagnostic procedure category where growth is driven by screening rate expansion and technology driven procedure refinement. Hologic's position reflects its integrated approach combining screening, imaging, and biopsy platforms. The growth opportunity lies in developing market screening program scale up, vacuum assisted system penetration in ambulatory settings, and AI enhanced targeting that improves diagnostic yield per procedure.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Rising breast cancer screening rates across developed and developing markets are increasing the volume of suspicious lesions requiring tissue biopsy for diagnosis.
• Growing preference for minimally invasive core needle biopsy over open surgical biopsy is increasing device utilization and reducing patient procedure burden.
• Expanding diagnostic imaging center infrastructure with integrated biopsy capability is creating new procedure capacity in ambulatory and community settings.

Key Market Constraints

• Needle gauge limitations and tissue sampling variability can affect diagnostic accuracy, particularly for small or deep lesions requiring precise targeting.
• Competition from liquid biopsy and other non invasive diagnostic technologies may reduce biopsy volumes for certain diagnostic applications over time.
• Reimbursement pressure on biopsy procedure fees constrains facility investment in premium vacuum assisted systems in some healthcare markets.

Key Opportunity Areas

• Integration of artificial intelligence with image guided biopsy systems is improving lesion targeting accuracy and procedure efficiency.
• Growing adoption of breast MRI and tomosynthesis screening is increasing detection of lesions that require biopsy, expanding procedure volumes.
• Developing market screening program expansion is creating first time biopsy device procurement demand across new healthcare facilities.

Segment-wise Analysis of the Breast Cancer Core Needle Biopsy Market

• Core Needle Biopsy Devices hold 46% of the respective segment in 2026.
• Breast Cancer Diagnosis hold 54% of the respective segment in 2026.
• Hospitals hold 62% of the respective segment in 2026.

Which Product Type Segment Leads the Breast Cancer Core Needle Biopsy Market?

Core needle biopsy devices account for 46% of the product type segment in 2026. Automated spring loaded biopsy needles in 14 gauge and 16 gauge configurations are the most commonly used devices for breast tissue sampling, providing histological specimens sufficient for definitive pathological diagnosis.

The segment benefits from established clinical protocols and broad availability across hospital and imaging center settings. Core needle biopsy is recommended by clinical guidelines as the preferred method for tissue sampling of suspicious breast lesions, supporting consistent procedural demand.

Which Application Segment Leads the Breast Cancer Core Needle Biopsy Market?

Breast cancer diagnosis accounts for 54% of the application segment in 2026. Tissue sampling of mammographically or ultrasonographically detected suspicious lesions for histological classification represents the primary clinical demand for core needle biopsy in breast imaging and oncology practice.

The segment is supported by organized breast cancer screening programs that generate consistent volumes of lesions requiring tissue diagnosis. Screening detected abnormalities including microcalcifications, mass lesions, and architectural distortions create the clinical pathway that drives biopsy device utilization.

Which End Use Segment Leads the Breast Cancer Core Needle Biopsy Market?

Hospitals account for 62% of the end use segment in 2026, reflecting the concentration of breast imaging departments with integrated biopsy capability in hospital settings. Radiology departments and breast centers within hospitals handle the majority of image guided core needle biopsy procedures.

Diagnostic imaging centers are growing as breast screening and biopsy procedures shift toward dedicated outpatient facilities. Specialty breast clinics contribute through concentrated biopsy volumes in facilities designed specifically for breast care and diagnosis.

Which Product Trend is Shaping the Next Phase of Growth in the Breast Cancer Core Needle Biopsy Market?

AI integrated image guided biopsy systems are emerging as the most significant technology trend in the market. These systems use artificial intelligence algorithms to assist in lesion identification, targeting, and biopsy planning, potentially improving diagnostic yield and reducing the number of non diagnostic or inadequate tissue samples.

The shift toward AI integration reflects the clinical demand for improved biopsy accuracy and efficiency. Radiologists performing image guided biopsies face challenges with small, subtle, or deep lesions where precise targeting affects diagnostic success. AI assisted targeting systems that provide real time guidance during the biopsy procedure have the potential to reduce repeat procedures, improve tissue sampling adequacy, and enhance overall diagnostic workflow efficiency.

Regional Outlook Across Key Markets

• China leads growth at 5.0%, supported by expanding breast cancer screening programs, growing diagnostic imaging capacity, and rising breast cancer detection rates.
• India at 4.7% reflects increasing breast cancer awareness, expanding hospital biopsy capability, and growing adoption of image guided tissue sampling techniques.
• North America remains the largest market with the USA at 4.5%, driven by established screening programs, high diagnostic imaging utilization, and premium device preference.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Breast Cancer Core Needle Biopsy in the United States

The U.S. breast cancer core needle biopsy market is projected to grow at a CAGR of 4.5% through 2036. Demand is supported by established screening programs, high imaging utilization, and premium device preference.

• Established screening programs sustain consistent biopsy procedure volumes.
• High diagnostic imaging utilization supports lesion detection and biopsy demand.
• Premium vacuum assisted device preference drives value growth.

Breast Cancer Core Needle Biopsy Demand Trends in China

The China breast cancer core needle biopsy market is projected to grow at a CAGR of 5.0% through 2036. Growth is supported by expanding screening programs and diagnostic imaging capacity.

• Screening program expansion increases lesion detection and biopsy volumes.
• Diagnostic imaging capacity growth creates new biopsy procedure capability.
• Rising breast cancer awareness improves screening participation rates.

India Breast Cancer Core Needle Biopsy Market Growth Assessment

The India breast cancer core needle biopsy market is projected to grow at a CAGR of 4.7% through 2036. Demand is supported by growing breast cancer awareness and expanding hospital biopsy capability.

• Breast cancer awareness campaigns increase screening and detection rates.
• Hospital biopsy capability expansion creates new procedure capacity.
• Image guided biopsy adoption improves diagnostic accuracy and access.

Japan Breast Cancer Core Needle Biopsy Market Demand Analysis

The Japan breast cancer core needle biopsy market is projected to grow at a CAGR of 4.3% through 2036. Demand is shaped by established screening infrastructure and aging demographics.

• Established screening infrastructure sustains consistent biopsy volumes.
• Aging demographics increase breast cancer detection and biopsy demand.
• Advanced imaging technology supports precision guided biopsy procedures.

Germany Breast Cancer Core Needle Biopsy Market Opportunity Outlook

The Germany breast cancer core needle biopsy market is projected to grow at a CAGR of 4.2% through 2036. Demand is supported by organized screening programs and clinical quality standards.

• Organized screening programs generate consistent biopsy procedure demand.
• Clinical quality standards sustain premium device procurement.
• Breast center certification requirements support standardized biopsy practice.

Competitive Benchmarking and Company Positioning

Breast Cancer Core Needle Biopsy Market Analysis By Company

• Hologic Inc. holds a leading position with approximately 24% share, supported by a broad product portfolio and established institutional relationships.
• Intact Medical Corporation, Ethicon Surgical Technologies, Gallini SRL participate meaningfully across specific categories and regional channels.
• Competition is shaped by product differentiation, regulatory approvals, institutional procurement, and geographic distribution.

The competitive landscape is moderately fragmented. Hologic Inc. leads through portfolio breadth and market presence. Intact Medical Corporation, Ethicon Surgical Technologies, Gallini SRL maintain relevance across specific niches. Strategic priorities include expanding product portfolios, strengthening distribution, and investing in next generation development.

Key Companies in the Breast Cancer Core Needle Biopsy Market

• Hologic Inc., Intact Medical Corporation, Ethicon Surgical Technologies, Gallini SRL are among the leading players globally.
• Leica Biosystems Nussloch GmbH, Argon Medical Devices, Encapsule Medical Devices LLC, Cook Medical Incorporated, Becton, Dickinson and Company, C.R. Bard Inc. hold positions across specific segments and regional markets.

Recent Industry Developments

• Hologic Inc. : Product Innovation / Biopsy Platform Enhancement (2025)
  • Hologic continued to advance its breast biopsy platform with imaging integration and workflow improvements, maintaining its position as the leading provider of breast biopsy solutions across mammography guided, ultrasound guided, and MRI guided procedures.
• Becton, Dickinson and Company : Product Portfolio / Biopsy Needle Updates (2025)
  • BD continued to expand its biopsy needle portfolio with updated configurations designed for improved tissue acquisition, ergonomic handling, and compatibility with multiple imaging guidance platforms.
• Argon Medical Devices : Market Expansion / Biopsy Device Distribution (2025)
  • Argon Medical Devices expanded distribution of its breast biopsy device portfolio across growing markets, supporting demand from new diagnostic imaging centers and hospital breast care programs.

Leading Companies Shaping the Breast Cancer Core Needle Biopsy Market

• Hologic Inc.
• Intact Medical Corporation
• Ethicon Surgical Technologies
• Gallini SRL
• Leica Biosystems Nussloch GmbH
• Argon Medical Devices
• Encapsule Medical Devices LLC
• Cook Medical Incorporated
• Becton, Dickinson and Company
• C.R. Bard Inc.

Sources and Research References

• Hologic Inc. Breast biopsy platform and imaging integration updates.
• Becton, Dickinson and Company. Biopsy needle portfolio and product updates.
• American College of Radiology. Breast imaging and biopsy practice guidelines.
• World Health Organization. Breast cancer screening and early detection recommendations.
• Primary interviews with breast radiologists, pathologists, hospital procurement officers, imaging center directors, and medical device distributors.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the breast cancer core needle biopsy market?
• How fast is the market expected to grow between 2026 and 2036?
• Which product type leads the market by 2026?
• Which application segment accounts for the highest demand?
• What factors are driving demand globally?
• How is AI integration influencing biopsy technology?
• Why is China the fastest growing market?
• Which countries show the fastest growth through 2036?
• Who are the key companies?
• How does Fact.MR estimate the forecast?

Breast Cancer Core Needle Biopsy Market Definition

The breast cancer core needle biopsy market covers automated core needle biopsy devices, vacuum assisted biopsy systems, manual biopsy needles, and associated accessories used for minimally invasive tissue sampling of breast lesions in image guided diagnostic settings. It includes sterile disposable devices, tissue preservation solutions, biopsy kits, and marking devices used across hospitals, diagnostic imaging centers, and specialty clinics for breast cancer diagnosis, lesion characterization, follow up diagnostics, and screening program support.

Breast Cancer Core Needle Biopsy Market Inclusions

• Global and regional market size and forecasts for 2026 to 2036 across product type, application, end use, technology, formulation, distribution channel, and region.
• Regional demand analysis based on breast cancer screening rates, biopsy procedure volumes, diagnostic imaging infrastructure, and healthcare spending.
• Pricing analysis across automated, vacuum assisted, and manual biopsy device categories.
• Competitive landscape including product portfolios, imaging integration capabilities, and distribution strategies.

Breast Cancer Core Needle Biopsy Market Exclusions

• Fine needle aspiration devices used for cytological rather than histological tissue sampling.
• Surgical excisional biopsy instruments not classified as core needle biopsy devices.
• Diagnostic imaging equipment including mammography, ultrasound, and MRI systems without integrated biopsy function.
• Liquid biopsy and other non tissue based breast cancer diagnostic products.

Breast Cancer Core Needle Biopsy Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 100+ secondary sources and benchmarks 50+ company product portfolios.
• Market sizing covers 30+ countries through a demand side model, supported by top down validation.
• Key inputs include industry procurement data, regulatory frameworks, technology adoption rates, and product pricing trends.
• The model cross checks demand with shipment volumes, pricing trends, channel mix, and product launch timelines.
• Primary validation includes 25+ interviews across manufacturers, distributors, healthcare providers, and end users.
• Final estimates go through supply validation, trade flow checks, and sensitivity testing.